Neridronate inhibits angiogenesis in vitro and in vivo

D. Ribatti, B. Nico, D. Mangieri, N. Maruotti, V. Longo, A. Vacca, F. P. Cantatore

Research output: Contribution to journalArticlepeer-review


The effects of the amino-bisphosphonate neridronate on endothelial cell functions involved in angiogenesis, namely, proliferation and morphogenesis on Matrigel were tested in vitro, whereas its effects on angiogenesis were studied in vivo, by using the chick embryo chorioallantoic membrane (CAM) assay. In vitro, neridronate inhibited endothelial cell proliferation in a dose-dependent fashion, peaking at 30 μM. At the same concentration, neridronate inhibited fibroblast growth factor-2 (FGF-2)-induced capillary-like tube formation in the morphogenesis assay on Matrigel. In vivo, when tested in the CAM assay, neridronate again displayed the capability to inhibit FGF-2-induced angiogenesis. Overall, these results suggest that anti-angiogenesis by neridronate could be used to treat a wide spectrum of angiogenesis-dependent diseases, including certain chronic inflammatory diseases and cancer.

Original languageEnglish
Pages (from-to)1094-1098
Number of pages5
JournalClinical Rheumatology
Issue number7
Publication statusPublished - Jul 2007


  • Anti-angiogenesis
  • Bisphosphonate
  • Chorioallantoic membrane
  • Endothelial cells
  • Neridronate

ASJC Scopus subject areas

  • Rheumatology
  • Immunology


Dive into the research topics of 'Neridronate inhibits angiogenesis in vitro and in vivo'. Together they form a unique fingerprint.

Cite this